DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

Similar documents
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

A drug development crossroad lies ahead

DMPK Overview. DMPK Overview. CYP i NDUCTi ON. P r OTeiN Bi NDi NG. CYP i NHi B i T i ON. r ADi OLABe L MASS BALANCe. X e NOGr AFT MODe LS

21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager

Your bridge to. better medicines

SPEED UP YOUR TIME TO MARKET

Antibody Discovery at Evotec

QPS Neuropharmacology Overview

Dermal Studies at CBI

Optimisation de votre programme de développement

ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY

Envigo Corporate & Industry Overview. Rutgers University

Eurofins ADME BIOANALYSES Your partner in drug development

Agreed with W. Cornell Graduate Program and Tri-I

The Right Molecules. Designed. Delivered.

The Aptuit Center for Drug Discovery & Development Verona, Italy

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

Hepatic ADME-Tox Products & Research Services

UNLEASH THE POWER OF PRECISION MEDICINE

Paving the way to FDA? tips and pitfalls. The Nextar start up support program Dr. Orna Dreazen- CEO

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

Delivering in vitro DM assay services

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

Introduction to Drug Design and Discovery

Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

A full-service CRO with integrated early-stage capabilities

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Addressing challenges in Drug Development and Quality Control with innovative solutions

to acquire Investor And Analyst Call Presentation January 4, 2008

Metabolite ID. Introduction

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

AT A GLANCE. inventivhealthclinical.com

How to Manage Metabolite Profiling Requests, the CRO Perspective. Dr Martha A Green Manager Qualitative Mass Spectrometry Charles River, Edinburgh

Jefferies Global Health Care Conference. June 1, 2015

PHARMATRAIN BASE COURSE MODULE 2: NON-CLINICAL, PHARMACEUTICAL AND EARLY CLINICAL DEVELOPMENT LEARNING OUTCOMES

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250

Explore the World of End-to-End. Integrated Lab Performance

ABF Pharmaceutical Services GmbH

MRC-NIHR National Phenome Centre

in full-service contract pharmaceutical development and manufacturing

Introduction to Drug Development in Commercializing Biomedical Technology

ADME : OVERVIEW AND CURRENT TOPICS COPYRIGHTED MATERIAL

Career Growth Areas in Physiology / Pharmacology

bioanalytical challenge Patrick Bennett PPD Biomarker Laboratories November 2015

NUVISAN GROUP. Our Philosophy

4/10/2017. Agenda. Overview: Biomarker Industry. + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and Challenges

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim

Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

Introduction of Development Center for Biotechnology TAIWAN

Drug Metabolism & Pharmacokinetics. Bridging Chemistry, Biology, Pharmacology and Toxicology, from discovery to IND/NDA.

Current Trends in GLP-like Analysis

Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell

Intertek Melbourn Company Presentation. MIBio 2016

Associate Director, LM Bioanalytical Services

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Contact:: (609) Details please visit our website:

How discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015

Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research

PHARMACEUTICAL TESTING

Fully Integrated Solutions

EARLY PHASE DEVELOPMENT SOLUTIONS

PPD LABORATORIES COMPREHENSIVE SERVICES

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

From Drug Discovery to IND Saving Time and Money Through Smart Study Design

Investor Presentation. September 2018

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

BIOANALYTICAL STRATEGY FOR IN VITRO METABOLITE SCREENING WITH EXACT MASS USING THE Q-Tof micro. Jose M. Castro-Perez 1, Carina Leandersson 2

European Bioanalysis Forum

Good Clinical Practice (GCP) & Clinical Trial Registries

Investor presentation. December 2018

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Expert decision support software for predicting the metabolic fate of chemicals in mammals.

Speakers Title & Biography

Bioanalytical Support to In Vitro Studies

THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

A Global CRO STRONGER TOGETHER

The room was more than 3/4 full with greater than 150 people in attendance.

SHANGHAI MEDICILON INC.

Informatics and High Resolution QTof MS. How can we ask better questions and get better answers in DMPK? Mark D. Wrona

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Bioanalytical Best Practice in Australia a CPR perspective. by Andrew Dinan Senior Director Bioanalytical Services CPR Pharma Services, Australia

Pharmaceutical LC/MS Solutions from Agilent Technologies

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

RAPIDD FIRE ARTICLE.

3M Drug Delivery Systems. April 26, 2011

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more:

SHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17

Asia A New Frontier for Clinical Research and Development

Adopting Virtual R&D in Drug Development

Workflow for PBPK Modeling to Support Pediatric Research and Development

We offer integral tailor-made solutions, providing our expertise, flexibility and capability from early stages to launch.

Agile, resourceful and personal no matter what. great people, great work, real results

Systems Sciences. Summer Short Courses University of California at San Diego. University of Nebraska Medical Center

Structure and content of an IMPD. What is required for first into man trial?

Solution Story: Beating the competition to market in drug development

Transcription:

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs

Introduction to QPS DMPK Services: For many, especially virtual, small and mid-size, pharmaceutical firms, outsourcing ADME studies to an experienced CRO such as QPS is a practical alternative to building or expanding an internal DMPK department. Outsourcing to QPS has many compelling advantages that are primarily associated with expanded expertise and improved cost effectiveness. HUMAN MASS BALANCE METABOLITE PROFILING TK MODELING METABOLITE IDENTIFICATION ADME FETUS RNAI THERAPEUTICS TISSUE DISTRIBUTION

The primary reasons why you should choose QPS as your preferred CRO for all your ADME sourcing needs. Direct Peer-to-Peer Interactions You get immediate access to a team of senior scientists that have 15+ years of pharmaceutical and biotech drug discovery and development experience. We will work with you to conduct the appropriate ADME studies across a broad range of compound structures and therapeutic targets. From Whole Body Autoradiography of a pregnant rat to Heart Autoradiography to Microautoradiography Furthermore, the same group of scientists also has additional 10+ years of CRO experience. Given this combination, QPS has breadth and depth from the perspective of the client as well as the service provider. You will benefit from direct peer-to-peer interactions and management of scientific, technical, and operational interactions by a seasoned scientist that has previously led discovery or development teams. Fast Turnaround Historical data clearly demonstrate that the direction taken by drug discovery and development is substantially influenced by ADME results. Our scientific experience, integrated services, and application of state-of-the-art bioanalytical equipment provides fast turnaround that will help you quickly arrive at go/no-go decisions thereby reducing your total developmental costs. Customer Focus Most of our senior level technical managers used to be involved with either contracting or monitoring out-sourced studies, so we understand exactly what is needed to be in a contracting partnership. We run your discovery and development programs with the ultimate care and commitment that you would expect from QPS.

MS 4 MS 3 MS 2 MS 1 MS 1 MS 4 MS 3 MS 2 Cost Effective Our DMPK department focuses on core services within our specific areas of expertise, and we integrate the various study components to gain additional efficiencies. This translates to improved overall project and time management which in turn translates to high quality, cost effectiveness and effective capacity utilization. QPS Delaware and Taiwan are both AAALAC accredited facilities and are both part of governmental GLP inspection programs. All regulatory-filing studies are performed in compliance according to the latest FDA or ICH or OECD guidance documents. QPS offers a full range of DMPK services including: Pharmacokinetics Formulation All Routes of Administration (including but not limited to: IV, PO, intraportal, intraduodenal and intracranial) Bioanalysis PK/TK Modeling PK/PD Modeling Xenograft Models Protein Binding Radiolabel Tissue Distribution (QWBA & Micro-Autoradiography) Mass Balance/Excretion/BDC Metabolite Profiling, ID & Radio-quantitation Consulting Program Development Consulting Mechanistic Studies ADME Summary for Regulatory Submission DDI / Metabolism CYP Inhibition/Induction Species Comparison Reaction Phenotyping Metabolite Profiling and Structural Elucidation

QPS is a reputable and profitable provider of world-class pharmaceutical development services, possessing unparalleled scientific expertise within our core competencies: DMPK, Toxicology, Bioanalysis, Translational Medicine, Early Stage Clinical, Phase 2-4 Clinical and Program Management. Call to arrange for a tour at one of QPS worldwide locations today NETHERLANDS USA TAIWAN INDIA QPS Taiwan QPS CTPS QPS Qualitix QPS Bio-Kinetic QPS HQ QPS Netherlands QPS Bioserve

Time is of the essence, so contact a member of the QPS Business Development Team today and find out what QPS can do for you North America Asia Europe - Wendy Nelson +1 508 543 0228 wendy.nelson@qps.com - Jerry Gromelski +1 570 451 3015 jerry.gromelski@qps.com - Marina Abanto +1 513 232 4772 marina.abanto@qps.com - Jim Cunningham +1 402 541 6041 jim.cunningham@qps.com - Jeff Moran +1 302 690 2163 jeff.moran@qps.com - Andrew Nehls +1 402 895 2022 andrew.nehls@qps.com - Dave Dehler +1 540 751 1325 dave.dehler@qps.com - Stacie Knebel +1 302 635 4341 stacie.knebel@qps.com - Alex Chang +886 2 2655 7555 alex.chang@qps-taiwan.com.tw - Manish Kalwani +91 40 2377 0873 74 manish@bioserve.co.in - Jelle Hempenius +31 50 304 8000 jelle.hempenius@qps.com - Fabien du Fraisse +44 7834 704426 fabien.du.fraisse@qps.com - Edwin van Vulpen +31 50 304 8000 edwin.van.vulpen@qps.com - Sylvia Demandewicz +32 477 752970 sylvia.demandewicz@qps.com HQ BD Office - Lily Rosa +1 512 350 2827 info@qps.com